N-terminal domain on dystroglycan enables LARGE1 to extend matriglycan on α-dystroglycan and prevents muscular dystrophy
eLife · 2023
DOI: 10.7554/elife.82811 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Hidehiko Okuma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Howard Hughes Medical Institute, Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, Department of Molecular Physiology and Bio…. Hauptthemen laut MEDLINE: Dystroglycans, Muscular Dystrophies, N-Acetylglucosaminyltransferases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NINDS NIH HHS, Howard Hughes Medical Institute.
Abstract (Originalsprache)
Dystroglycan (DG) requires extensive post-translational processing and O -glycosylation to function as a receptor for extracellular matrix (ECM) proteins containing laminin-G (LG) domains. Matriglycan is an elongated polysaccharide of alternating xylose (Xyl) and glucuronic acid (GlcA) that binds with high affinity to ECM proteins with LG domains and is uniquely synthesized on α-dystroglycan (α-DG) by like-acetylglucosaminyltransferase-1 (LARGE1). Defects in the post-translational processing or O -glycosylation of α-DG that result in a shorter form of matriglycan reduce the size of α-DG and decrease laminin binding, leading to various forms of muscular dystrophy. Previously, we demonstrated that protein O -mannose kinase (POMK) is required for LARGE1 to generate full-length matriglycan on α-DG (~150–250 kDa) (Walimbe et al., 2020). Here, we show that LARGE1 can only synthesize a short, non-elongated form of matriglycan in mouse skeletal muscle that lacks the DG N-terminus (α-DGN), resulting in an ~100–125 kDa α-DG. This smaller form of α-DG binds laminin and maintains specific force but does not prevent muscle pathophysiology, including reduced force production after eccentric contractions (ECs) or abnormalities in the neuromuscular junctions. Collectively, our study demonstrates that α-DGN, like POMK, is required for LARGE1 to extend matriglycan to its full mature length on α-DG and thus prevent muscle pathophysiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Howard Hughes Medical Institute, Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, Department of Molecular Physiology and Biophysics and Department of Neurology, Roy J. and Lucille A. Carver Coll…
- Department Pharmaceutical Sciences, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
- Department of Neurology, School of Medicine, Teikyo University, Tokyo, Japan.
ORCID-Profile: Hidehiko Okuma, David Venzke, Kevin P Campbell
Förderung
- NHLBI NIH HHS
- NINDS NIH HHS
- Howard Hughes Medical Institute
- NIH HHS
- Paul D. Wellstone Muscular Dystrophy Specialized Research Center
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Okuma, H., Hord, J. M., Chandel, I., Venzke, D., Anderson, M. E., Walimbe, A. S., Joseph, S., Gastel, Z., Hara, Y., Saito, F., Matsumura, K., & Campbell, K. P. (2023). N-terminal domain on dystroglycan enables LARGE1 to extend matriglycan on α-dystroglycan and prevents muscular dystrophy. eLife. https://doi.org/10.7554/elife.82811
Vancouver
Okuma H, Hord JM, Chandel I, Venzke D, Anderson ME, Walimbe AS, et al. N-terminal domain on dystroglycan enables LARGE1 to extend matriglycan on α-dystroglycan and prevents muscular dystrophy. eLife. 2023. doi:10.7554/elife.82811
BibTeX
@article{Okuma2023,
author = {Okuma, Hidehiko and Hord, Jeffrey M and Chandel, Ishita and Venzke, David and Anderson, Mary E and Walimbe, Ameya S and Joseph, Soumya and Gastel, Zeita and Hara, Yuji and Saito, Fumiaki and Matsumura, Kiichiro and Campbell, Kevin P},
title = {N-terminal domain on dystroglycan enables LARGE1 to extend matriglycan on α-dystroglycan and prevents muscular dystrophy},
journal = {eLife},
year = {2023},
doi = {10.7554/elife.82811}
}
EUVIMED